Need professional-grade analysis? Visit stockanalysis.com
$920.64M
41.67
N/A
N/A
Price Chart
Risk-Adjusted Performance
DNA Biomed Solns (DNA) Price Performance
DNA Biomed Solns (DNA) trades on TA in ILS. The company is classified in the Consumer Cyclical sector under the Lodging industry. The stock currently trades at ILS103.80, down 0.48% from the previous close.
Over the past year, DNA has traded between a low of ILS86.50 and a high of ILS123.90. The stock has gained 1.0% over this period. It is currently 16.2% below its 52-week high.
DNA Biomed Solns has a market capitalization of $920.64M, with a price-to-earnings ratio of 41.67.
About DNA Biomed Solns
Dna Group (T.R.) Ltd, together with its subsidiaries, engages in the development, manufacturing, and marketing of patented ultrasound systems in Israel, North America, East Asia, and internationally. It provides systems for diagnosing bone strength and density, as well as for monitoring calcium leakage (osteoporosis) in adults and children. The company offers its products for use by skilled physicians, nurses, and operators in hospitals and clinics, as well as in pharmacies and other places. In addition, it engages in the development of oral drugs. The company was formerly known as D.N.A Biomedical Solutions Ltd. and changed its name to Dna Group (T.R.) Ltd in November 2022. Dna Group (T.R.) Ltd was incorporated in 2004 and is based in Tel Aviv-Yafo, Israel.
Compare DNA Biomed Solns
Side-by-side comparison against top Consumer Cyclical peers.
Company Info
- Sector
- Consumer Cyclical
- Industry
- Lodging
- Exchange
- TA
- Currency
- ILS
- Country
- Israel
Financial Metrics
- Revenue (TTM)
- $306,000
- EBITDA
- $-1,510,000
- Profit Margin
- 168.63%
- EPS (TTM)
- N/A
- Book Value
- 0.80
Technical Indicators
- 52 Week High
- ₪123.90
- 52 Week Low
- ₪86.00
- 50 Day MA
- ₪119.89
- 200 Day MA
- ₪108.29
- Beta
- -0.01
Valuation
- Trailing P/E
- 41.67
- Forward P/E
- N/A
- Price/Sales
- 3008.61
- Price/Book
- 10.20
- Enterprise Value
- $931.29M